Agonistic anti-CD27 antibody ameliorates EAE by suppressing IL-17 production., PMID:35856659
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes., PMID:35886899
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma., PMID:36055572
CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions., PMID:36091071
Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles., PMID:36095190
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy., PMID:36100308
When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders., PMID:36209991
Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep., PMID:36211974
Identification and characterization of blocking nanobodies against human CD70., PMID:36239354
Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment., PMID:36394119
CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19., PMID:36537906
Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities., PMID:36745503
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy., PMID:36779592
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance., PMID:36787696
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia., PMID:36932256
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer., PMID:36970072
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models., PMID:37093350
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056
Generation of a CD70-Specific Fusion Nanobody with IgG Recruiting Capacity for Tumor Killing., PMID:37361386
Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes., PMID:37371066
METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer., PMID:37648786
PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases., PMID:37696593
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study., PMID:37914483
Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc., PMID:37965342
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391
Benzoic acid, 4-hydroxy-, methyl ester from Smilax zeylanica Linn emerges as a potent inhibitor of CD27/CD70 signaling pathway., PMID:38353477
ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study., PMID:38480552
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma., PMID:38583184
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment., PMID:38637886
Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models., PMID:38646638
Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer., PMID:38730739
Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD., PMID:39197208
CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study., PMID:39510586
CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond., PMID:39570653
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML., PMID:39571145
A mechanistic, functional, and clinical perspective on targeting CD70 in cancer., PMID:39725151
Direct Inhibitory Effect of HTLV-1-Infected T Cells on the Production of Anti-Ro/SS-A Antibody by B Cells from Patients with Sjögren's Syndrome., PMID:39775490
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies., PMID:39864030
Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes., PMID:39867912
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells., PMID:39906740
Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics., PMID:40015924
CD8α and CD70 mark human natural killer cell populations which differ in cytotoxicity., PMID:40046047
Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease., PMID:40078987
CD70 recruitment to the immunological synapse is dependent on CD20 in B cells., PMID:40232798
CD70-targeted cancer theranostics: Progress and challenges., PMID:40250430
CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study., PMID:40306966
The CD70-CD27 axis in cancer immunotherapy: Predictive biomarker and therapeutic target., PMID:40388162
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study., PMID:40404633
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621
For research use only. Not for human or drug use.
